Drug Resistance Profile Among HIV-1 Infections Experiencing ART with Low-Level Viral Load in Guangdong China During 2011–2022: A Retrospective Study

References

• Daltro ACB, Almeida CS, Unfried AGC, de Aquino TR, Travassos AGÁ. Virological failure and adherence to antiretroviral therapy in adolescents and young adults living with human immunodeficiency virus. Trop Med Int Health. 2023;28(3):162–174. doi:10.1111/tmi.13854
   PubMed Web of Science ®Google Scholar
• 1.14 million people infected with HIV in China. Available from: https://www.shine.cn/news/nation/2112018939/. Accessed December 3, 2021.
   Google Scholar
• Crespo-Bermejo C, de Arellano ER, Lara-Aguilar V, et al. Persistent low-Level viremia in persons living with HIV undertreatment: an unresolved status. Virulence. 2021;12(1):2919–2931. doi:10.1080/21505594.2021.2004743
   PubMed Web of Science ®Google Scholar
• Chen J, He Y, Zhong H, et al. Transcriptome analysis of CD4+ T cells from HIV-infected individuals receiving ART with LLV revealed novel transcription factors regulating HIV-1 promoter activity. Virol Sin. 2023;S1995–820X(23):22. doi:10.1016/j.virs.2023.03.001
   Google Scholar
• McCluskey SM, Siedner MJ, Marconi VC. Management of virologic failure and HIV drug resistance. Infect Dis Clin North Am. 2019;33(3):707–742. doi:10.1016/j.idc.2019.05.004
   PubMed Web of Science ®Google Scholar
• Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA. 2005;293(7):817–829. doi:10.1001/jama.293.7.817
   PubMed Web of Science ®Google Scholar
• Santoro MM, Fabeni L, Armenia D, et al. Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels. Clin Infect Dis. 2014;58(8):1156–1164. doi:10.1093/cid/ciu020
   PubMed Web of Science ®Google Scholar
• World Health Organization. Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach. Geneva: World Health Organization; 2021.
   Google Scholar
• U.S. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents inAdults and Adolescents with HIV; 2021. Available from: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines. Accessed July 28, 2023.
   Google Scholar
• European AIDS clinical society. European guidelines for treatment of HIV infected adults in Europe; 2019. Available from: https://eacsociety.org/files/2019_guide.lines-10.0_final.pdf. Accessed July 27, 2023.
   Google Scholar
• Temereanca A, Ruta S. Strategies to overcome HIV drug resistance-current and future perspectives. Front Microbiol. 2023;14:1133407. doi:10.3389/fmicb.2023.1133407
   PubMed Web of Science ®Google Scholar
• Galli L, Parisi MR, Poli A, et al. Burden of disease in PWH harboring a multidrug-resistant virus: data from the PRESTIGIO registry. Open Forum Infect Dis. 2020;7(11):ofaa456. doi:10.1093/ofid/ofaa456
   PubMed Web of Science ®Google Scholar
• Li L, Li H, Lan Y, et al. Impact of low level viremia on the antiviral effect of human immunodeficiency virus/acquired immunodeficiency syndrome patients received anti-retroviral therapy. Chinese J Infect Dis. 2021;39(8):470–474. Chinese. doi:10.3760/cma.j.cn311365-20200703-00693
   Google Scholar
• Li Q, Chen M, Zhao H, et al. Persistent low-level viremia is an independent risk factor for virologic failure: a retrospective cohort study in China. Infect Drug Resist. 2021;14:4529–4537. doi:10.2147/IDR.S332924
   PubMed Web of Science ®Google Scholar
• Swenson LC, Min JE, Woods CK, et al. HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure. AIDS. 2014;28(8):1125–1134. doi:10.1097/QAD.0000000000000203
   PubMed Web of Science ®Google Scholar
• Bareng OT, Choga WT, Maphorisa ST, et al. HIV-1C in-House RNA-based genotyping assay for detection of drug resistance mutations in samples with low-level viral loads. Infect Drug Resist. 2022;15:7565–7576. doi:10.2147/IDR.S388816
   PubMed Web of Science ®Google Scholar
• People’s government of Guangdong Province: the overall AIDS epidemic in Guangdong Province is at a low epidemic level. Available from:http://www.gd.gov.cn/zwgk/zdlyxxgkzl/ylws/content/post_4056940.html. Accessed December 2, 2022.
   Google Scholar
• Li Q, Yu F, Song C, et al. A concentration method for HIV drug resistance testing in low-level viremia samples. Biomed Res Int. 2022;2022:2100254. doi:10.1155/2022/2100254
   PubMed Web of Science ®Google Scholar
• Li Q, Yu F, Song C, et al. HIV-1 genotypic resistance testing using sanger and next-generation sequencing in adults with low-level viremia in China. Infect Drug Resist. 2022;15:6711–6722. doi:10.2147/IDR.S387215
   PubMed Web of Science ®Google Scholar
• Yuan D, Zhou Y, Shi L, et al. HIV-1 drug resistance profiles of low-level viremia patients and factors associated with the treatment effect of ART-treated patients: a cross-sectional study in Jiangsu, China. Front Public Health. 2022;10:944990. doi:10.3389/fpubh.2022.944990
   PubMed Web of Science ®Google Scholar
• Lan Y, He X, Li L, et al. Complicated genotypes circulating among treatment naïve HIV-1 patients in Guangzhou, China. Infect Genet Evol. 2021;87:104673. doi:10.1016/j.meegid.2020.104673
   PubMed Web of Science ®Google Scholar
• Struck D, Lawyer G, Ternes AM, Schmit JC, Bercoff DP. COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res. 2014;42(18):e144. doi:10.1093/nar/gku739
   PubMed Web of Science ®Google Scholar
• Pineda-Peña AC, Faria NR, Imbrechts S, et al. Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools. Infect Genet Evol. 2013;19:337–348. doi:10.1016/j.meegid.2013.04.032
   PubMed Web of Science ®Google Scholar
• Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol. 2010;59(3):307–321. doi:10.1093/sysbio/syq010
   PubMed Web of Science ®Google Scholar
• Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42(11):1608–1618. doi:10.1086/503914
   PubMed Web of Science ®Google Scholar
• Assoumou L, Charpentier C, Recordon-Pinson P, et al. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study. J Antimicrob Chemother. 2017;72(6):1769–1773. doi:10.1093/jac/dkx042
   PubMed Web of Science ®Google Scholar
• Bangalee A, Hans L, Steegen K. Feasibility and clinical relevance of HIV-1 drug resistance testing in patients with low-level viraemia in South Africa. J Antimicrob Chemother. 2021;76(10):2659–2665. doi:10.1093/jac/dkab220
   PubMed Web of Science ®Google Scholar
• Lyu S, Bai R, Dai M, et al. Features analysis of HIV-1 genotype resistance in patients with low-level viremia after antiretroviral therapy. Chin J AIDS. 2022;28(10):1187–1190. Chinese. doi:10.13419/j.cnki.aids.2022.10.16
   Google Scholar
• He X, Xing H, Ruan Y, et al. A comprehensive mapping of HIV-1 genotypes in various risk groups and regions across China based on a nationwide molecular epidemiologic survey. PLoS One. 2012;7(10):e47289. doi:10.1371/journal.pone.0047289
   PubMed Web of Science ®Google Scholar
• Zhou PP, Yu G, Kuang YQ, et al. Rapid and complicated HIV genotype expansion among high-risk groups in Guangdong Province, China. BMC Infect Dis. 2019;19(1):185. doi:10.1186/s12879-019-3788-7
   PubMedGoogle Scholar
• Lan Y, Li L, He X, et al. Transmitted drug resistance and transmission clusters among HIV-1 treatment-naïve patients in Guangdong, China: a cross-sectional study. Virol J. 2021;18(1):181. doi:10.1186/s12985-021-01653-6
   PubMed Web of Science ®Google Scholar
• Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3’-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA. 1993;90(12):5653–5656. doi:10.1073/pnas.90.12.5653
   PubMed Web of Science ®Google Scholar
• Melikian GL, Rhee SY, Varghese V, et al. Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing. J Antimicrob Chemother. 2014;69(1):12–20. doi:10.1093/jac/dkt316
   PubMed Web of Science ®Google Scholar
• Rhee SY, Kassaye SG, Barrow G, Sundaramurthi JC, Jordan MR, Shafer RW. HIV-1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimates. J Int AIDS Soc. 2020;23(9):e25611. doi:10.1002/jia2.25611
   PubMed Web of Science ®Google Scholar
• Panichsillapakit T, Smith DM, Wertheim JO, Richman DD, Little SJ, Mehta SR. Prevalence of transmitted HIV drug resistance among recently infected persons in San Diego, CA 1996–2013. J Acquir Immune Defic Syndr. 2016;71(2):228–236. doi:10.1097/QAI.0000000000000831
   PubMed Web of Science ®Google Scholar
• Rossetti B, Di Giambenedetto S, Torti C, et al. Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016. HIV Med. 2018;19(9):619–628. doi:10.1111/hiv.12640
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang Y, Li H, et al. Natural presence of the V179D and K103R/V179D mutations associated with resistance to nonnucleoside reverse transcriptase inhibitors in HIV-1 CRF65_cpx strains. BMC Infect Dis. 2020;20(1):313. doi:10.1186/s12879-020-05007-5
   PubMed Web of Science ®Google Scholar
• Gonzalez-Serna A, Min JE, Woods C, et al. Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals. Clin Infect Dis. 2014;58(8):1165–1173. doi:10.1093/cid/ciu019
   PubMed Web of Science ®Google Scholar
• Gonzalez-Serna A, Swenson LC, Watson B, et al. A single untimed plasma drug concentration measurement during low-level HIV viremia predicts virologic failure. Clin Microbiol Infect. 2016;22(12):1004.e9–1004.e16. doi:10.1016/j.cmi.2016.08.012
   PubMed Web of Science ®Google Scholar
• Inzaule SC, Bertagnolio S, Kityo CM, et al. The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa. AIDS. 2020;34(10):1559–1566. doi:10.1097/QAD.0000000000002588
   PubMed Web of Science ®Google Scholar
• Lan Y, Deng X, Li L, et al. HIV-1 drug resistance and genetic transmission networks among MSM failing antiretroviral therapy in South China 2014–2019. Infect Drug Resist. 2021;14:2977–2989. doi:10.2147/IDR.S317187
   PubMed Web of Science ®Google Scholar
• Cai X, Lan Y, Li J, et al. Analysis on drug resistance in HIV/AIDS patients with HAART through different infection routes in Guangdong. Chin J AIDS. 2015;21(5):369–372. Chinese. doi:10.13419/j.cnki.aids.2015.05.06
   Google Scholar
• Yang Z, Wei S, Liu J, et al. Characterization of HIV-1 subtypes and drug resistance mutations in Henan Province, China (2017–2019). Arch Virol. 2020;165(6):1453–1461. doi:10.1007/s00705-020-04606-6
   PubMed Web of Science ®Google Scholar
• Chen J, Liu Y, Liu S, et al. HIV-1 drug resistance, distribution of subtypes, and drug resistance-associated mutations in virologic failure individuals in Chengdu, Southwest China, 2014–2016. Biomed Res Int. 2020;2020:5894124. doi:10.1155/2020/5894124
   PubMed Web of Science ®Google Scholar